Today, a Director at VolitionRX (NYSE: VNRX), Guy Archibald Innes, bought shares of VNRX for $99.99K.
Following this transaction Guy Archibald Innes’ holding in the company was increased by 3.83% to a total of $2.61 million. In addition to Guy Archibald Innes, 2 other VNRX executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Currently, VolitionRX has an average volume of 25.5K.
Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $5.67, reflecting a -66.7% downside. Starting in March 2015, VNRX received 29 Buy ratings in a row. Four different firms, including Maxim Group and Oppenheimer, currently also have a Buy rating on the stock.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid.
